Navigation Links
Savient Provides Update on Pegloticase BLA
Date:2/12/2009

icular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA (pegloticase), and the market for KRYSTEXXA (pegloticase), are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of pegloticase and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of pegloticase; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in ongoing or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. USAID Provides Malaria Assistance to Zimbabwe
3. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. American Dairy Provides Business Update
6. Alfacell Provides ONCONASE(R) NDA Submission Update
7. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... Toronto (PRWEB) September 23, 2014 ... the Canadian specialty market, is now providing U.S. ... its new 160,000-square-foot distribution center coupled with its ... Canadian healthcare industry has historically been difficult for ... to government regulation complexities. As a result of ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 The print ... of the Metro, with a circulation of approximately 327,720 ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... features an exclusive interview with Michael Landsberg, host of ...
(Date:9/23/2014)... 2014 Antibiotics revolutionized health care in the ... killed thousands of people. But bacteria are also ... bacteria are popping up more frequently. This week,s ... of new antibiotics and discusses the prospects for ... Why should you finish your pills if you ...
(Date:9/23/2014)... to what is often assumed about single parents, particularly ... The Kinsey Institute has found that single parents of ... as often as singles without children -- and more ... study, "Dating and Sexual Behavior Among Single Parents of ... in the Journal of Sex Research prior ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 On September 23, ... Keith Simmons for an episode. Simmons is the founder of ... believed the audience would like to know. At the start ... the idea to start this magazine?” Simmons replied by saying, ... sales person. In 2005, I quit that and decided to ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... Society for Gastrointestinal Endoscopy (ASGE) and the American Society ... new white paper on the potential role of endoscopic ... like Type 2 diabetes. The white paper ... in both GIE: Gastrointestinal Endoscopy, the peer-reviewed ...
... standards for teaching women and clinicians how to perform ... to detect lumps earlier and save lives. Widely-publicized ... of cancer. The Center for Disease Control reports that ... most common cancer among American females. The National ...
... keep blood vessels open to treat heart disease are ... the Journal of Interventional Cardiology . A case ... of the Detroit Medical Center Cardiovascular Institute, and her ... after the recently marketed Ion stent (Boston Scientific, Natick, ...
... of organic horticultural crops frequently fall below those of ... of organic production. Researchers recently studied the growth and ... with vermicompost and compared the results with plants grown ... area is needed to provide a base of information ...
... has found that people are willing to pay up to 29.91 ... Researchers surveyed the public in the two major urban centres ... were willing to pay in council tax or rent/mortgage payments for ... willing to pay more for greener spaces with greater tree coverage. ...
... poisonous snakes, a group of researchers at the University of ... small black, yellow and red serpent called the Texas coral ... insights into chronic and acute pain and provides new ... combat pain. The venom contains a toxic mixture of ...
Cached Medicine News:Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 2Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 3Health News:Public willing to pay more for greener urban spaces 2Health News:Public willing to pay more for greener urban spaces 3Health News:Snake spills venomous secrets 2Health News:Snake spills venomous secrets 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: